Last reviewed · How we verify
NCT03691337
Fascia Iliaca Blocks for Total Hip Arthroplasty
Phase 4 trial testing Marcaine 0.25 % Injectable Solution in THA in 75 participants. Completed in 4 December 2019.
12 November 2019
Quick facts
| Lead sponsor | New York School of Regional Anesthesia |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 75 |
| Start date | 15 May 2018 |
| Primary completion | 12 November 2019 |
| Estimated completion | 4 December 2019 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- Marcaine 0.25 % Injectable Solution — full drug profile →
- Marcaine 0.25 % Injectable Solution — full drug profile →
- Sodium chloride (Sodium Chloride) — full drug profile →
Conditions studied
- THA — all drugs for THA →
Sponsor
New York School of Regional Anesthesia
Who can join
18 and older, any sex, with THA. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The development of minimal-incision techniques for total hip arthroplasty (THA) with preservation of soft tissue is generally associated with reduction of postoperative pain and increased patient comfort. Although this technique requires a smaller incision than other approaches used for hip surgery, adequate postoperative pain management remains crucial for enhanced recovery and early rehabilitation. The fascia iliaca block (FIB) is commonly used to enhance analgesia after hip replacement surgery, however the effect of FIB volume on analgesia quality and sensory-motor blockade have not been adequately studied. In this study, total postsurgical opioid consumption (morphine equivalents IV in hospital and oral at home) through the first postoperative week will be compared and extent and duration of sensory motor block through the 2-day inpatient stay will be evaluated.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03691337
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Marcaine 0.25 % Injectable Solution
Trials testing the same drug.
- NCT05898087 — Subpectoral Bupivacaine for Pain Management in Adolescent Reduction Mammaplasty · Phase 4 · recruiting
Other recruiting trials for THA
Currently open trials in the same condition.
- NCT06807866 — Duloxetine for Perioperative Pain in Hip Arthroplasty: A RCT · Phase 4 · recruiting
- NCT06831045 — Bikini vs Longitudinal Incision in Direct Anterior Approach (DAA) Total Hip Arthroplasty (THA) · NA · recruiting
Other New York School of Regional Anesthesia trials
Trials by the same sponsor.
- NCT03649763 — Onset and Duration of Forearm Nerve Blockade · Phase 4 · completed
- NCT03206320 — Topical Lidocaine for Needle Insertion and Injection Pain · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03691337 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by New York School of Regional Anesthesia
- Last refreshed: 10 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03691337.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing